Insilico Medicine, a Hong Kong-based global leader in end-to-end artificial intelligence for target discovery, small molecule chemistry, and clinical development, closed a $255m Series C financing.
The round was led by Warburg Pincus with participation from current investors Qiming Venture Partners, Pavilion Capital, Eight Roads Ventures, Lilly Asia Ventures, Sinovation Ventures, BOLD Capital Partners, Formic Ventures, Baidu Ventures, and new investors CPE, OrbiMed, Mirae Asset Capital, B Capital Group, Deerfield Management, Maison Capital, Lake Bleu Capital, President International Development Corporation, Sequoia Capital China and Sage Partners. In conjunction with the funding, Min Fang, Managing Director at Warburg Pincus, will join Insilico Medicine’s Board of Directors.
The company intends to use the funds to progress its current therapeutic programs into human clinical trials, initiate multiple new programs for novel and difficult targets, and further develop its AI and drug discovery capabilities.
Led by Alex Zhavoronkov, PhD, founder and CEO, Insilico Medicine develops artificial intelligence systems that utilize deep generative models, reinforcement learning (RL), transformers, and other modern machine learning techniques for the generation of new molecular structures with specific properties. The company also develops software for the generation of synthetic biological data, target identification, and the prediction of clinical trials outcomes.
Since its inception in 2014, Insilico Medicine has raised over $310 million from expert pharmaceutical, and technology investors, and has applied for over 30 patents.